167 related articles for article (PubMed ID: 28090317)
1. All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia.
Yoshida T; Mihara K; Takei Y; Yanagihara K; Kubo T; Bhattacharyya J; Imai C; Mino T; Takihara Y; Ichinohe T
Clin Transl Immunology; 2016 Dec; 5(12):e116. PubMed ID: 28090317
[TBL] [Abstract][Full Text] [Related]
2. Anti-Acute Myeloid Leukemia Activity of CD38-CAR-T Cells with PI3Kδ Downregulation.
An N; Pan Y; Yang L; Zhang Q; Deng S; Zhang Q; Du X
Mol Pharm; 2023 May; 20(5):2426-2435. PubMed ID: 37021820
[TBL] [Abstract][Full Text] [Related]
3. CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.
Gurney M; Stikvoort A; Nolan E; Kirkham-McCarthy L; Khoruzhenko S; Shivakumar R; Zweegman S; Van de Donk NWCJ; Mutis T; Szegezdi E; Sarkar S; O'Dwyer M
Haematologica; 2022 Feb; 107(2):437-445. PubMed ID: 33375774
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha.
Drach J; McQueen T; Engel H; Andreeff M; Robertson KA; Collins SJ; Malavasi F; Mehta K
Cancer Res; 1994 Apr; 54(7):1746-52. PubMed ID: 7511050
[TBL] [Abstract][Full Text] [Related]
5. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia].
Wang ZZ; Lu Y; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):192-197. PubMed ID: 32311887
[No Abstract] [Full Text] [Related]
6. Retinoic acid induction of CD38 antigen expression on normal and leukemic human myeloid cells: relationship with cell differentiation.
Prus E; Fibach E
Leuk Lymphoma; 2003 Apr; 44(4):691-8. PubMed ID: 12769347
[TBL] [Abstract][Full Text] [Related]
7. All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma.
Peng Z; Wang J; Guo J; Li X; Wang S; Xie Y; Jiang H; Wang Y; Wang M; Hu M; Li Q; Wang Y; Mi JQ; Liu Z
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918219
[TBL] [Abstract][Full Text] [Related]
8. Expanding anti-CD38 immunotherapy for lymphoid malignancies.
Wang X; Yu X; Li W; Neeli P; Liu M; Li L; Zhang M; Fang X; Young KH; Li Y
J Exp Clin Cancer Res; 2022 Jun; 41(1):210. PubMed ID: 35765110
[TBL] [Abstract][Full Text] [Related]
9. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
10. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
11. [Research on the effect of PD-L1 overexpression on CLL-1 CAR-T anti-acute myeloid leukemia].
Lin GQ; Zhang YM; Kang LQ; Yu L; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):829-835. PubMed ID: 33190440
[No Abstract] [Full Text] [Related]
12. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
Mihara K; Yoshida T; Takei Y; Sasaki N; Takihara Y; Kuroda J; Ichinohe T
J Hematol Oncol; 2017 Jun; 10(1):116. PubMed ID: 28595585
[TBL] [Abstract][Full Text] [Related]
13. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
14. [Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell].
Meng YS; Ma XX; Meng XQ; Wei R; Liu W; Ai GW; Zhang YX
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3406-10. PubMed ID: 18476539
[TBL] [Abstract][Full Text] [Related]
15. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
[TBL] [Abstract][Full Text] [Related]
16. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression.
Bradbury DA; Aldington S; Zhu YM; Russell NH
Br J Haematol; 1996 Sep; 94(4):671-5. PubMed ID: 8826891
[TBL] [Abstract][Full Text] [Related]
18. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
[TBL] [Abstract][Full Text] [Related]
19. Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation.
Iriyama N; Yuan B; Hatta Y; Takagi N; Takei M
Cancer Cell Int; 2016; 16():37. PubMed ID: 27182202
[TBL] [Abstract][Full Text] [Related]
20. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells.
Wang Y; Xu Y; Li S; Liu J; Xing Y; Xing H; Tian Z; Tang K; Rao Q; Wang M; Wang J
J Hematol Oncol; 2018 May; 11(1):60. PubMed ID: 29716633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
